← Leaderboards
Michael A Schwarzschild
Massachusetts General Hospital
$27,249,495
Attributed
$30,545,475
Total exposure
20
Grants
15
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $5.5M · FY2005–23$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$30,485,475 · 19
FDA$60,000 · 1
By mechanism
U01$20,948,883 · 2
R01$7,307,937 · 4
K24$953,881 · 1
R21$929,919 · 2
R13$238,000 · 7
R03$82,660 · 1
Top collaborators
- Earl Ray Dorsey6 shared
- Tanya Simuni Simuni6 shared
- Lara M Mangravite5 shared
- David K. Simon2 shared
- Solveig Sieberts1 shared
Most similar at Massachusetts General Hospital
Same institution · by research overlap
- Howard L Liber$3,228,829
- Fumito Ichinose$9,083,343
- Jasper Smits$5,956,982
- Yoshinaga Saeki$406,678
- Solveig Sieberts$1,534,204
Others in their field
Top investigators on “Parkinson Disease”
- Tatiana M. Foroud · Indiana Univ-Purdue Univ At Indianapolis$92,426,001
- David M Anderson · University Of Washington$40,483,703
- Daniel M Corcos · Northwestern University$37,632,589
- Joel Synes Perlmutter · Washington University$37,192,743
- Jerrold L Vitek · University Of Minnesota$35,135,315
- Joseph B Martin · Harvard University (Medical School)$26,652,023
Research focus
Parkinson DiseaseResearch PersonnelDesignClinical TrialsProgramsFoundationsInsightBaseMolecularUrateInosineGeneticNeurodegenerative DisordersInvestmentsMotorMutationAttenuatedNeuroprotective AgentsAntioxidantsNeurobiologyFuturePlaySerumNerve Degeneration
Grant awards (57)
Urate-LRRK2 interactions in Parkinson's disease$385,473
R01 · FY2023 · NS · contact PI
Planning for Prevention of Parkinson's Disease: a trial design forum$60,000
R13 · FY2023 · FD · contact PI
Tele-Health Extension for Phase 3 Parkinson's Disease Trial Cohorts$774,161
U01 · FY2022 · NS · contact PI
Urate-LRRK2 interactions in Parkinson's disease$388,381
R01 · FY2022 · NS · contact PI
Tele-Health Extension for Phase 3 Parkinson's Disease Trial Cohorts$778,151
U01 · FY2021 · NS · contact PI
Urate-LRRK2 interactions in Parkinson's disease$391,611
R01 · FY2021 · NS · contact PI
2019 Parkinson Study Group Symposium and Training$25,000
R13 · FY2021 · NS · contact PI
Tele-Health Extension for Phase 3 Parkinson's Disease Trial Cohorts$786,024
U01 · FY2020 · NS · contact PI
Urate-LRRK2 interactions in Parkinson's disease$403,753
R01 · FY2020 · NS · contact PI
2019 Parkinson Study Group Symposium and Training$25,000
R13 · FY2020 · NS · contact PI
Tele-Health Extension for Phase 3 Parkinson's Disease Trial Cohorts$790,164
U01 · FY2019 · NS · contact PI
Urate-LRRK2 interactions in Parkinson's disease$425,791
R01 · FY2019 · NS · contact PI
Tele-Health Extension for Phase 3 Parkinson's Disease Trial Cohorts$100,000
U01 · FY2019 · NS · contact PI
2019 Parkinson Study Group Symposium and Training$25,000
R13 · FY2019 · NS · contact PI
Phase 3 trial of inosine for Parkinson's disease CCC$1
U01 · FY2019 · NS · contact PI
Phase 3 trial of inosine for Parkinson's disease CCC$2,874,019
U01 · FY2018 · NS · contact PI
Tele-Health Extension for Phase 3 Parkinson's Disease Trial Cohorts$852,847
U01 · FY2018 · NS · contact PI
Phase 3 trial of inosine for Parkinson's disease CCC$3,388,840
U01 · FY2017 · NS · contact PI
2017 Parkinson Study Group Symposium and Training$25,000
U13 · FY2017 · NS · contact PI
Phase 3 trial of inosine for Parkinson's disease CCC$5,334,882
U01 · FY2016 · NS · contact PI
Phase 3 trial of inosine for Parkinson's disease CCC$98,970
U01 · FY2016 · NS · contact PI
2016 Parkinson Study Group Symposium and Training$20,000
R13 · FY2016 · NS · contact PI
Phase 3 trial of inosine for Parkinson's disease CCC$5,170,824
U01 · FY2015 · NS · contact PI
Role of urate in protecting mitochondrial function in the brain$252,323
R21 · FY2014 · NS · contact PI
2014 Parkinson Study Group Symposium and Training$20,000
R13 · FY2014 · NS · contact PI
Role of urate in protecting mitochondrial function in the brain$217,616
R21 · FY2013 · NS · contact PI
2013 Parkinson's Study Group Symposium$20,000
R13 · FY2013 · NS · contact PI
Pursuing purine pathways to clinical trials for Parkinson's disease$198,486
K24 · FY2012 · NS · contact PI
Pursuing purine pathways to clinical trials for Parkinson's disease$195,853
K24 · FY2011 · NS · contact PI
Translational Foundation of Adenosine Antagonist Use for Dyskinesias$352,708
R01 · FY2010 · NS · contact PI
Uric Acid:novel therapeutic target for Parkinson's Disease$210,574
R21 · FY2010 · NS · contact PI
Pursuing purine pathways to clinical trials for Parkinson's disease$191,092
K24 · FY2010 · NS · contact PI
Translational Foundation of Adenosine Antagonist Use for Dyskinesias$358,641
R01 · FY2009 · NS · contact PI
Uric Acid:novel therapeutic target for Parkinson's Disease$249,406
R21 · FY2009 · NS · contact PI
Pursuing purine pathways to clinical trials for Parkinson's disease$186,468
K24 · FY2009 · NS · contact PI
Translational Foundation of Adenosine Antagonist Use for Dyskinesias$78,686
R01 · FY2009 · NS · contact PI
Translational Foundation of Adenosine Antagonist Use for Dyskinesias$360,795
R01 · FY2008 · NS · contact PI
Pursuing purinergic pathways to clinical trials for Parkinson's disease$181,982
K24 · FY2008 · NS · contact PI
Translational Foundation of Adenosine Antagonist Use for Dyskinesias$468,511
R01 · FY2007 · NS · contact PI
Translational Foundation of Adenosine Antagonist Use for Dyskinesias$108,918
R01 · FY2007 · NS · contact PI
Translational Foundation of Adenosine Antagonist Use for Dyskinesias$375,419
R01 · FY2006 · NS · contact PI
ASSESS THE EFFICACY & SAFETY OF CEP-1347 IN PTS W/EARLY PARKINSON'S DISEASE$14,375
M01 · FY2006 · RR · contact PI
Targeting Adenosine A2A Receptors in Parkinson's Disease$10,000
R13 · FY2006 · NS · contact PI
Novel Neuroprotection by Caffeine in Parkinson's Disease$335,050
R01 · FY2005 · ES
A2A Adenosine Receptors in Psychostimulant Sensitization$291,800
R01 · FY2005 · DA
ASSESS THE EFFICACY &SAFETY OF CEP-1347 IN PTS W/EARLY PARKINSON'S DISEASE$21,039
M01 · FY2005 · RR
Novel Neuroprotection by Caffeine in Parkinson's Disease$335,050
R01 · FY2004 · ES
A2A Adenosine Receptors in Psychostimulant Sensitization$291,800
R01 · FY2004 · DA
Assess the Efficacy &Safety of CEP-1347 in Pts w/Early Parkinson's Disease$23,781
M01 · FY2004 · RR
Novel Neuroprotection by Caffeine in Parkinson's Disease$335,050
R01 · FY2003 · ES
A2A Adenosine Receptors in Psychostimulant Sensitization$291,800
R01 · FY2003 · DA
Novel Neuroprotection by Caffeine in Parkinson's Disease$360,050
R01 · FY2002 · ES
A2A Adenosine Receptors in Psychostimulant Sensitization$316,800
R01 · FY2002 · DA
Translating A2A Receptor Biology into Novel PD Therapy$33,000
R13 · FY2002 · NS
Novel Neuroprotection by Caffeine in Parkinson's Disease$360,050
R01 · FY2001 · ES
A2A Adenosine Receptors in Psychostimulant Sensitization$291,800
R01 · FY2001 · DA
A2A ADENOSINE RECEPTOR--A NOVEL ROLE IN NEUROPROTECTION$82,660
R03 · FY2000 · AG